Abstract: The present invention relates to a method of treating necrotizing enterocolitis in a patient, which includes administering a pharmaceutical composition that includes carbon monoxide to the patient.
Abstract: A calcium phosphate cement suitable for use in dental and bone prosthesis is disclosed, which include calcium phosphate particles having a diameter of 0.05 to 100 microns, wherein said calcium phosphate particles on their surfaces have whiskers or fine crystals having a width ranging from 1 to 100 nm and a length ranging from 1 to 1000 nm.
Abstract: A method of treating neoplastic disease in a human or animal patient is provided comprising administering to the patient an anti-neoplastic effective amount of a composition comprising as the sole pharmaceutically active components (a) copper gluconate or copper orotate; (b) sodium salicylate; (c) vitamin C; (d) manganese gluconate or manganese orotate; and optionally one or more of (e) iron gluconate or iron orotate; (f) sublimed sulphur; and (g) zinc gluconate or zinc orotate.
Abstract: Described is an intra-mammary teat sealant and a corresponding method of forming a physical barrier in the teat canal of a non-human animal for prophylactic treatment of mammary disorders during the animal's dry period. The method includes the step of infusing a bismuth-free teat seal formulation into the teat canal of the animal. The method also prevents the formation of black spot defect in dairy products, especially cheddar cheese, made from the milk of animals so treated.
Abstract: Disclosed are methods for attracting and thereby controlling bedbugs. One volatizes a synthetic pheromone and generates infrared radiation adjacent the location and exposes bedbugs thereto. The pheromone volatizer and/or radiation generator are preferably incorporated into traps, bait stations and monitoring stations.
Type:
Grant
Filed:
January 12, 2007
Date of Patent:
February 22, 2011
Inventors:
Eric D. Siljander, Stephen Takács, Regine Gries, Gerhard Gries
Abstract: A method for reducing pathogens in the gastrointestinal tract of a live animal comprising orally administering to the animal an effective amount of an aqueous antimicrobial solution, wherein the aqueous antimicrobial solution comprises from about 0.01% to about 0.1% by weight of a metal chlorite and a sufficient quantity of an acid having a first pKa of from about 2.0 to about 4.4 to adjust the pH of the aqueous antimicrobial solution to about 2.2 to about 4.5 and to maintain the chlorite ion concentration in the form of chlorous acid to not more than about 35% by weight of the total chlorite ion present in the aqueous antimicrobial solution, is disclosed.
Type:
Grant
Filed:
July 21, 2005
Date of Patent:
February 15, 2011
Assignee:
Ecolab Inc.
Inventors:
C. Cayce Warf, Jr., G. Kere Kemp, John Richards
Abstract: The invention relates to a medical implant made of a metallic material. After fulfilling its temporary support function, the implant is degraded by corrosion at a predetermined rate. Negative long-term effects are thus avoided.
Type:
Grant
Filed:
July 17, 1998
Date of Patent:
February 1, 2011
Assignees:
Alfons Fischer, Jacqueline Hausdorf, Eva Heublein
Abstract: The present invention provides a self tanning cosmetic containing 0.2-20.0 mass % of dihydroxyacetone and 0.1-10.0 mass % of an inorganic pigment powder whose surface is treated with silica coating followed by a hydrophobing treatment. The present invention provides a cosmetic that has superior storage stability, is free of discoloration and odor generation, and achieves both the decorative effect of the pigment immediately following application and the long term dyeing effect of dihydroxyacetone.
Abstract: A controlled release melatonin tablet having a slow release nucleus of melatonin, hydroxypropyl methylcellulose, a lubricant, a volume excipient and a glidant, wherein 95% of the melatonin is released within 5 hours in an oscillating tray containing gastric/intestinal juice at 37° C. and a fast release cortex coating on said nucleus of melatonin, hydroxypropyl methylcellulose and a volume excipient, wherein at least 95% of the melatonin is released within 10 minutes in an oscillating tray containing gastric/intestinal juice at 37° C.
Abstract: Novel pharmaceutical gallium compositions, including gallium complexes having increased oral bioavailability relative to uncomplexed gallium salts are disclosed. Such compositions are useful in the treatment of conditions and diseases in which inhibition of abnormally increased calcium resorption is desired, including cancer, hypercalcemia, osteoporosis, osteopenia and Paget's disease. Methods for preparation and treatment are also provided.
Abstract: An ascorbic acid-based composition and related method for the treatment of aging, photo-damaged or inflamed skin is disclosed. The composition includes water and ascorbic acid, at least a portion of which has generally been pretreated by being dissolved under relatively high temperature and concentration conditions. The composition typically includes at least about 5.0% (w/v) ascorbic acid formulated to have a pH above 3.5. 10 to 50% of the ascorbic acid is pretreated ascorbic acid. The composition may also include a non-toxic zinc salt, a tyrosine compound, and/or pharmaceutically acceptable carrier. The composition may include an anti-inflammatory compound, such as aminosugar and/or sulfur-containing anti-inflammatory compound. Embodiments containing an aminosugar such as glucosamine are further useful for treating rosacea and other inflammatory skin ailments. The composition may be administered in a variety of forms suitable for topical application on skin.
Abstract: An ascorbic acid-based composition and related method for the treatment of aging, photo-damaged or inflamed skin is disclosed. The composition includes water and ascorbic acid, at least a portion of which has generally been pretreated by being dissolved under relatively high temperature and concentration conditions. The composition typically includes at least about 5.0% (w/v) ascorbic acid formulated to have a pH above 3.5. 10 to 50% of the ascorbic acid is pretreated ascorbic acid. The composition may also include a non-toxic zinc salt, a tyrosine compound, and/or pharmaceutically acceptable carrier. The composition may include an anti-inflammatory compound, such as aminosugar and/or sulfur-containing anti-inflammatory compound. Embodiments containing an aminosugar such as glucosamine are further useful for treating rosacea and other inflammatory skin ailments. The composition may be administered in a variety of forms suitable for topical application on skin.
Abstract: Food supplement compositions and their methods of use in increasing lean mass and/or muscle size and/or strength in individuals, particularly, athletes is described. The food supplements described comprise a substance which increases nitric oxide production in the body, and, a source of amino acids. Other food supplements described comprise a substance which can enhance and/or mimic insulin activity, and a source of amino acids. The food supplement compositions described are suitable for supplementing the diet of an athlete and particularly for enhancing an athlete's muscle size or strength.
Type:
Grant
Filed:
March 11, 2004
Date of Patent:
September 14, 2010
Assignee:
Northern Innovations and Formulations Corp.
Inventors:
Paul T. Gardiner, Derek E. Woodgate, Mark S. Gilbert, Robert W. Thoburn
Abstract: Compositions and methods employing the compositions for attracting arthropods. The compositions comprise at least one compound of formula I and at least one compound from group II.
Type:
Grant
Filed:
September 26, 2003
Date of Patent:
August 10, 2010
Inventors:
Ulrich Bernier, Donald Barnard, Matthew Booth, Daniel Kline, Kenneth Posey, Richard Yost
Abstract: The invention provides UV-barrier formulations which result in products which effectively resist the transmission of ultraviolet light therethrough. The invention also provides UV-barrier formulations which result in products with improved resistance to ultraviolet light. In particular, the invention provides UV barrier formulations for polyester resins that have improved resistance to ultraviolet radiation, and significantly reduce ultraviolet light transmission in the resulting resin products. The invention also provides products and manufacturing processes based on the above formulations.
Type:
Grant
Filed:
June 30, 2004
Date of Patent:
July 27, 2010
Assignee:
Dak Americas, LLC
Inventors:
Karl H. Buchanan, Helen J. Codd, Peter S. Kezios
Abstract: A pharmaceutical composition is provided comprised of a physiologically acceptable source of assimilable copper, a source of salicylic acid or a physiologically acceptable derivative thereof, and vitamin C.
Abstract: The invention provides a particulate composition adapted for forming a bone graft substitute cement upon mixing with an aqueous solution, including i) a calcium sulfate hemihydrate powder having a bimodal particle distribution and a median particle size of about 5 to about 20 microns, wherein the calcium sulfate hemihydrate is present at a concentration of at least about 70 weight percent based on the total weight of the particulate composition; ii) a monocalcium phosphate monohydrate powder; and iii) a ?-tricalcium phosphate powder having a median particle size of less than about 20 microns. Bone graft substitute cements made therefrom, a bone graft substitute kit comprising the particulate composition, methods of making and using the particulate composition, and articles made from the bone graft substitute cement are also provided.
Type:
Grant
Filed:
September 8, 2006
Date of Patent:
July 13, 2010
Assignee:
Wright Medical Technology, Inc.
Inventors:
Jon P. Moseley, Michael E. Carroll, Jonathan D. McCanless
Abstract: There is provided a new technology that will allow the formulation of pharmaceutically active organic acid products at relatively high pH during storage. This affords the advantages of avoiding formulation with the acid form of the product, yet when the product is used, the pH will be reduced via a chemical reaction, thus forming the organic acid which is the active form of the product. A by-product of the reaction is a significant increase in temperature, thus adding to the efficacy of the organic acid.
Abstract: Processes are provided for preparing mupirocin calcium dihydrate from pseudomonic acid in a two phase system by using an organic carboxylate. A highly pure composition of amorphous mupirocin calcium is provided, and processes for its preparation by solvent removal, lyophilization and precipitation with use of an anti-solvent. Pharmaceutical compositions of amorphous form, and methods of using them to treat infections are also provided. Also provided are combined processes for preparing mupirocin calcium dihydrate and amorphous, by producing amorphous form first, followed by conversion of amorphous form into the dihydrate through crystallization from an aqueous solution. Also provided are processes for removing the water of crystallization of the dihydrate to obtain mupirocin calcium anhydrate.
Abstract: The present invention relates to oral pharmaceutical preparations in the form of pellets in which a benzimidazole compound is stabilized by combining it with microcrystalline cellulose.
Type:
Grant
Filed:
July 16, 2003
Date of Patent:
June 8, 2010
Assignee:
Ratiopharm, GmbH
Inventors:
Frank Muskulus, Peter Kraaβ, Andrea Burgenmeister